Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Go back to Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)| (NASDAQ: JAGX) | Delayed: 2.61 +0.36 (16.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.25 | 52 Week High | $4.60 | |||
| Open | $2.28 | 52 Week Low | $0.81 | |||
| Day High | $2.77 | P/E | N/A | |||
| Day Low | $2.26 | EPS | $0.00 | |||
| Volume | 271,242 | |||||
